BetaGlue Technologies SpA news
Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Gaia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas
BetaGlue Technologies has appointed four new managers, strengthening the team across strategic fields for its business development: Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Gaia Bisaccioni joined the company in S
- Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Caia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas
- Clinical developments continue on the advanced cancer radiotherapy platform, BAT-90, as the first breast cancer patient was treated
Milan, October 19, 2022 - BetaGlue Technologies, a highly innovative company working in the Life Sciences sector, announces the appointment of four new managers, strengthening the team across
Theraised capitalwill give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90, thus opening a new chapter in the fight against cancer
BetaGlue Technologieshasclosed a EUR 10 million equity financing round:Fin Posillipo(Petrone Group),Kairos Partners SGR,LIFTT(Venture Capital led by Stefano Buono, founder of AAA),Neva Sgr(Intesa Sanpaolo Group),ProfequycapitalandRomedwill be joining the company’s capital ,
The first clinicalfindingshave shown that BAT-90makes it possible to treat onlythe area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatmentefficacy and patient safety
BetaGlue Technologieshasenrolledthe first patientin a clinical trialwithBAT-90, the company’s cancer radiotherapy platform. The first clinical findings have shown thatBAT-90 makes it possible to treat only the area where the tumour is located, while a
- Fin Posillipo (Petrone Group], Kairos Partners SGR, LIFTT, Neva Sgr (Intesa Sanpaoh Group), Profequycapital and Romedjoined the share capital Innogest Capital and Panakes Partners reinvest
- The financing will give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90, and accelerate access to the Safe-Biopsy Device market, thus opening a new chapter in the fight against cancer
Milan, July 19,2022 - BetaGlue Technologies
- The first clinical results have shown that BAT-90 innovative radiotherapy platform makes it possible to treat only the area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatment efficacy and patient safety
- CEO/CMO, Dr. Antonino Amato, said: "The confirmation in this first patient of the previous findings from the pre-clinical studies with BAT-90 opens up tremendous perspectives for therapeutic nuclear medicine in oncology, which will
BetaGlue (www.betaglue.com), an innovative Italian company in the field of interventional oncology today announced the appointment of its new Board of Directors, composed by investors representatives, independent industry experts and company CEO.
New members of the board are Riccardo Palmisano, Company’s Chairman and Geoffroy De Ribains, as independent Board member. Antonino